LIPOCINE INC. (NASDAQ:LPCN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security Holders |
On June 13, 2017, the Company held its annual general meeting of
shareholders, at which time the following items were voted upon:
| (1) |
Election of Directors. The Companys shareholders elected for a one-year term five persons nominated for election as directors. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors: |
| Nominee | For | Withheld |
Broker Non-Vote |
|||
| Dr. Mahesh V. Patel | 9,069,594 | 678,150 | 7,636,144 | |||
| Dr. Stephen A Hill | 8,808,210 | 939,534 | 7,636,144 | |||
| Jeffrey A. Fink | 9,674,002 | 73,742 | 7,636,144 | |||
| John W. Higuchi | 7,697,674 | 2,050,070 | 7,636,144 | |||
| Dr. Richard Dana Ono | 8,893,861 | 853,883 | 7,636,144 |
There were no abstentions with respect to the election of
directors.
| (2) |
Ratification of Appointment of Independent Registered Public Accounting Firm. The Companys shareholders voted upon and ratified the appointment of KPMG LLP as the Companys independent registered public accountants for the fiscal year ending December 31, 2017. The following table sets forth the vote of the shareholders at the meeting with respect to the appointment of KPMG LLP: |
| For | Against | Abstain | ||
| 17,148,980 | 84,864 | 150,044 |
There were no broker non-votes in the ratification of appointment
of KPMG LLP as the Companys independent registered public
accountants for the fiscal year ending December 31, 2017.
About LIPOCINE INC. (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company’s additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip’ral promicellar drug delivery technology platform. Lip’ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
